We also found that CPT1A exhibited good efficacy in differentiating patients with breast cancer from patients with benign breast disease (Fig. 4b, left; AUC, 0.807; 95% CI, 0.759–0.855). This evidence concerns the gene CPT1A and breast carcinoma.